Lanreotide (Mytolac) 60 mg and 120 mg per 0.5 ml syringe

Affected product

The supplier, Boucher & Muir, has run out of the following strengths of lanreotide:

Presentation: inj 60 mg per 0.5 ml, 0.5 ml syringe

• Brand: Mytolac
• Pharmacode: 2698145
• Subsidy: $382.77
• Measure / Qty: per 1

Presentation: Inj 120 mg per 0.5 ml, 0.5 ml syringe

• Brand: Mytolac
• Pharmacode: 2698161 
• Subsidy: $646.70
• Measure / Qty: per 1

The 90 mg (Pharmacode: 2698153) is available. 

Schedule listing for lanreotide(external link)

HML listing for lanreotide(external link)

People who use lanreotide

You may need to talk to the person who prescribed your lanreotide about the best way to respond to this supply issue.

A different brand of the 60 mg lanreotide is available. It contains the same active ingredient in the same amount.

It has not been approved by Medsafe for use in New Zealand, this means your doctor and pharmacist have extra steps they need to follow before giving you the lanreotide.  

Alternative 60 mg strength

The supplier has found an alternative product for this strength. It was listed from 1 July 2025 and is available. It is not Medsafe approved. Which means it will need to be prescribed and dispensed in line with section 29 of the Medicines Act.

• Presentation: inj 60 mg per 0.5 ml, 0.5 ml syringe
• Brand: Mytolac (s29)
• Pharmacode: 2709597
• Subsidy: $382.77
• Measure / Qty: per 1

Prescribing and supplying an unapproved medicine

Section 29 of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as, a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, this will allow patients to be able to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link) 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website (external link)

Medsafe’s section 29 Declaration / Notification Form [DOC](external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Expected resupply

The supplier the shipment of 120 mg Mytolac has arrived and should be available at pharmacies again by late September 2025.

The supplier expects to have registered stock of the 60 mg Mytolac available again in 2026.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)